Kidney Cancer

Radical Nephrectomy Linked With Worse Kidney Function, Survival

Radical Nephrectomy Linked With Worse Kidney Function, Survival

By

Patients who underwent radical nephrectomy had 2-fold greater decline in eGFR decline and 2-fold greater mortality compared with those who had a partial nephrectomy.

Cabozantinib Improves Survival, Response in Bone-metastatic RCC

Cabozantinib Improves Survival, Response in Bone-metastatic RCC

Patients who received cabozantinib were also less likely to have skeletal-related events (23% vs 29% with everolimus).

3D Printing Surgical Models for Kidney Cancer Care

3D Printing Surgical Models for Kidney Cancer Care

By

Renal & Urology News spoke with Jonathan Silberstein, MD, about creating surgical models using a 3D printer.

SABR for Renal Cell Carcinoma Offers Excellent Outcomes

SABR for Renal Cell Carcinoma Offers Excellent Outcomes

By

Stereotactic ablative radiotherapy is associated with high 2- and 4-year rates of local cancer control and progression-free and cancer-specific survival.

Conversion of Robotic Partial to Radical Nephrectomy Is Uncommon

Conversion of Robotic Partial to Radical Nephrectomy Is Uncommon

By

In a multinational, prospective study, just 5% of cases converted.

Adverse Events Up for Autoimmune Disease Pts on Checkpoint Inhibitors

Adverse Events Up for Autoimmune Disease Pts on Checkpoint Inhibitors

Most patients with cancer, autoimmune disease have improvement in events without discontinuing therapy.

Fatigue Tied With Sorafenib, Sunitinib Use in Renal Cell Carcinoma

Fatigue Tied With Sorafenib, Sunitinib Use in Renal Cell Carcinoma

Although TKIs improve outcomes, they are still associated with toxicities common with cancer therapies, such as fatigue.

Partial Nephrectomy Improves Survival in cT1b RCC Cases

Partial Nephrectomy Improves Survival in cT1b RCC Cases

By

Partial nephrectomy was associated with decreased odds of death versus radical nephrectomy among patients with cT1b but not cT2 renal cell carcinoma.

FDA Approves Cabometyx for First-Line Treatment of Advanced RCC

FDA Approves Cabometyx for First-Line Treatment of Advanced RCC

Treatment with cabozantinib led to a clinically meaningful improvement in progression-free survival compared with sunitinib.

Cytoreductive Nephrectomy Benefits for Metastatic RCC Demonstrated

Cytoreductive Nephrectomy Benefits for Metastatic RCC Demonstrated

By

Patients who underwent cytoreductive nephrectomy for metastatic non-clear cell renal cell carcinoma had a significantly decreased risk of cancer-related mortality.

Kidney Cancer Bone Metastasis Predictors Id'd

Kidney Cancer Bone Metastasis Predictors Id'd

By

Levels of alkaline phosphatase, calcium, and hemoglobin can independently predict bone metastasis in patients with renal cell carcinoma, Chinese investigators report.

FDA Approves Sunitinib for Adjuvant Treatment of RCC

FDA Approves Sunitinib for Adjuvant Treatment of RCC

By

At 5 years, 59.3% of patients treated with sunitinib were free from recurrence versus 51.3% who received placebo.

Radical Nephrectomy Costs, Operating Time Greater With Robotics

Radical Nephrectomy Costs, Operating Time Greater With Robotics

By

Robotic-assisted radical nephrectomy (RN) is associated with higher hospital costs and prolonged operating time compared with laparoscopic RN.

Blood Transfusion Predicts Worse Outcomes After Nephrectomy for RCC

Blood Transfusion Predicts Worse Outcomes After Nephrectomy for RCC

By

Perioperative blood transfusion is associated with increased risks of tumor recurrence, metastatic progression, and cancer-related mortality.

Overweight-Related Cancers Common in the US

Overweight-Related Cancers Common in the US

40% of cancer diagnoses tied to extra weight; rate higher in older individuals, females.

RCC Subtypes Affect Post-Surgery Cancer-Related Mortality Risk

RCC Subtypes Affect Post-Surgery Cancer-Related Mortality Risk

By

Patients with papillary versus clear cell renal cell carcinoma have a 24% decreased risk of dying from their cancer.

CKD Risk Lower With Partial Nephrectomy

CKD Risk Lower With Partial Nephrectomy

By

In a study, partial nephrectomy was associated with a 66% lower risk for stage 4 or higher CKD versus radical nephrectomy.

Various Neurological Complications Tied to Anti-PD-1 Therapy

Various Neurological Complications Tied to Anti-PD-1 Therapy

The researchers found that 2.9% of the 347 patients treated with anti-PD-1 monoclonal antibodies developed subacute onset of neurological complications.

FDA Approves First Biosimilar for Kidney Cancer Treatment

FDA Approves First Biosimilar for Kidney Cancer Treatment

Mvasi, which is approved to treat colorectal, lung, brain, kidney, and cervical cancer, was found to be biosimilar to the drug Avastin.

Immunotherapy Superior to Sunitinib for Front-Line mRCC Treatment

Immunotherapy Superior to Sunitinib for Front-Line mRCC Treatment

By

Checkpoint inhibitor combination of nivolumab plus ipilimumab improved progression-free and overall survival compared with sunitinib.

Upfront Cabozantinib for Advanced RCC Improves Outcomes

Upfront Cabozantinib for Advanced RCC Improves Outcomes

By

Cabozantinib reduced the risk of disease progression or death compared with sunitinib among patients with previously untreated advanced renal cell carcinoma.

Early NLR Changes Predict mRCC Immunotherapy Outcomes

Early NLR Changes Predict mRCC Immunotherapy Outcomes

By

Rises and decreases in neutrophil-to-lymphocyte ratio at 6 weeks after treatment with anti-PD-1/PD-L1 immune checkpoint blockade is associated with progression-free and overall survival.

Energy Dense Diet Increases Obesity-Related Cancer Risk

Energy Dense Diet Increases Obesity-Related Cancer Risk

The increased risk for obesity-related cancer was seen among women who were normal weight at enrollment.

Geriatric Consultation Uncommon in Kidney Cancer Surgery

Geriatric Consultation Uncommon in Kidney Cancer Surgery

Participant age and comorbidity burden appeared to be consistent determinants of use of services, although hospital-level variation was also noted.

Combo Immunotherapy May Change Treatment for Kidney Cancer

Combo Immunotherapy May Change Treatment for Kidney Cancer

Response rates of the combination therapy increasing from 20% to 40%.

Targeted Multigene Panel Testing Useful for Hereditary Kidney Cancer

Targeted Multigene Panel Testing Useful for Hereditary Kidney Cancer

The most commonly altered genes were folliculin and fumarate hydratase in 1.8% and 1.3%, respectively.

Video: New Drug Proves Effective For Renal Cell Cancer Patients

Video: New Drug Proves Effective For Renal Cell Cancer Patients

Nivolumab combined with ipilimumab revealed manageable safety, antitumor activity and favorable responses garnering potential long-term benefits.

Type of Long-term Response to Targeted mRCC Therapy Affects Outcomes

Type of Long-term Response to Targeted mRCC Therapy Affects Outcomes

By

Patients who have a complete response to 2 or more years of anti-VEGF treatment have the best progression-free and overall survival.

What Not to Eat After Nephrectomy

What Not to Eat After Nephrectomy

By

Both urologists and nephrologists provide follow-up and continuity of care to patients after cancer nephrectomy.

BMI, Belly Fat Suggest Obesity-Related Cancer Risk

BMI, Belly Fat Suggest Obesity-Related Cancer Risk

BMI and location of excess body fat on the body are good indicators of obesity-related cancer risk.

Sign Up for Free e-newsletters